Translational Lung Cancer Research is a leading journal dedicated to advancing the field of oncology, particularly focusing on groundbreaking discoveries in lung cancer treatment and management. Published by AME Publishing Company, this journal boasts an impressive Q1 classification in the 2023 Oncology category, reflecting its significant contribution to the scientific community, with an outstanding Scopus rank of #92 out of 404 in Medicine _ Oncology, placing it in the 77th percentile. With its commitment to open access, the journal fosters international collaboration and accessibility, making cutting-edge research available to a wide audience. The scope of Translational Lung Cancer Research encompasses clinical trials, experimental studies, and translational research that bridge the gap between laboratory findings and clinical applications. Researchers, professionals, and students seeking to keep abreast of the latest developments in lung cancer research will find invaluable insights within its pages. For further information, please contact at FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG.

ORAL ONCOLOGY is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of oncology with a specific focus on oral diseases and cancers. Since its inception in 1996, this esteemed journal has provided a platform for high-quality research that addresses critical issues in oral surgery, cancer research, and related disciplines. With impressive rankings in Q1 in Oncology and Q1 in Oral Surgery, and recognized as Rank #1 in Dentistry and Oral Surgery by Scopus, ORAL ONCOLOGY consistently publishes impactful articles that contribute significantly to our understanding of oral cancers. The journal is committed to sharing pioneering findings that enhance clinical practices and improve patient outcomes. As a non-open access journal, it provides readers with exclusive access to cutting-edge research, ensuring that professionals, researchers, and students are at the forefront of developments in the field. Situated in the United Kingdom, ORAL ONCOLOGY serves as an indispensable resource for those dedicated to advancing oral health and oncology research through rigorous scientific inquiry and collaboration.

Lung Cancer Management, published by FUTURE MEDICINE LTD, is a premier academic journal dedicated to the evolving field of oncology and respiratory medicine. With an ISSN of 1758-1966 and an E-ISSN of 1758-1974, this journal offers a platform for the dissemination of cutting-edge research, clinical studies, and expert reviews, all focusing on the latest advances in lung cancer treatment and management. Despite being a relatively new entry since its inception in 2014 and achieving its converged years from 2020 to 2024, it has already established itself in the Q3 quartile for both oncology and pulmonary and respiratory medicine as of 2023, according to category quartiles rankings. With a Scopus ranking of #98 in the category of Pulmonary and Respiratory Medicine and #266 in Oncology, the journal reflects a commitment to quality and relevance in its content. Although it does not offer open access, it remains a crucial resource for researchers, clinicians, and students seeking to stay informed about the latest developments and practical approaches in lung cancer management. The journal is accessible from its base in the United Kingdom, at UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ensuring that it caters to a global audience eager to explore and contribute to this vital field of medicine.

SEMINARS IN RADIATION ONCOLOGY is a premier journal published by W B SAUNDERS CO-ELSEVIER INC, dedicated to advancing the field of radiation oncology through high-quality research and comprehensive reviews. With an impressive impact factor and a notable HIndex, this journal holds a prominent place within the academic community, particularly illustrated by its Q2 ranking in both Cancer Research and Oncology, and a Q1 ranking in Radiology, Nuclear Medicine, and Imaging as of 2023. Since its inception in 1991, the journal has served as a vital resource for researchers, clinicians, and healthcare professionals, facilitating the exchange of innovative ideas and practices that shape the future of cancer treatment. While the journal is not open access, it offers essential insights into the latest advancements in the field, catering to a diverse audience eager to expand their knowledge and improve patient outcomes in the realm of radiation therapy.

Current Oncology is a prominent open-access journal dedicated to the field of oncology, published by MDPI in Switzerland. With an ISSN of 1198-0052 and E-ISSN 1718-7729, this esteemed journal has been providing valuable insights since its inception in 1998 and continues to publish cutting-edge research through 2024. Recognized for its contribution to the medical community, Current Oncology holds a 2023 Q2 category rank in Oncology and is positioned at the 41st percentile among its peers in Scopus rankings. As a hub for innovation and discussion in cancer research, it offers a plethora of articles that span various aspects of oncology, making it an essential resource for researchers, professionals, and students alike. Since becoming fully open-access in 2006, it provides expanded accessibility to groundbreaking studies and findings, fostering collaboration and knowledge exchange across the global research community. With its central location in Basel, Switzerland, Current Oncology plays a pivotal role in advancing oncology's frontiers.

Reports of Practical Oncology and Radiotherapy is a distinguished open-access journal dedicated to advancing the fields of oncology, radiotherapy, and cancer research. Published by VIA MEDICA since 2001, this journal serves as a critical platform for disseminating innovative research and practical findings that impact clinical practices and patient outcomes. With an emphasis on fostering collaboration and knowledge exchange among researchers, clinicians, and students, the journal has positioned itself within the Q3 and Q4 categories of renowned directories in oncology, radiology, and nuclear medicine as of 2023. Based in Gdansk, Poland, it provides unrestricted access to its articles, ensuring that crucial research reaches a wide audience. This dedication to open access reflects the journal's commitment to transparency and innovation in the fight against cancer, making it an invaluable resource in this vital field of study.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.